A new at-home injection has been approved for use on the NHS offering a significant breakthrough for approximately 1,500 individuals in England and Wales living with a rare heart condition.
Vutrisiran will be available for patients suffering from transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a debilitating illness where the liver-produced protein transthyretin misfolds, leading to deposits that stiffen the heart. Without intervention, this progressive condition can tragically culminate in heart failure.
Vutrisiran, sold under the brand name Amvuttra and made by Alnylam Pharmaceuticals, works by binding to, and stifling messenger RNA (mRNA) to reduce the amount of transthyretin made by the liver.
The injection, taken every three months by patients in their own home, has been recommended by Nice as a treatment option for some adults with ATTR-CM.
Source: The Independent (21 November 2025)
Recommended Comments
Create an account or sign in to comment